Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide,with anaplastic lymphoma kinase(ALK)fusion mutations accounting for approximately 4％-9％of cases.In recent years,there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer(NSCLC)patients.This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and dis-cuss its advantages and challenges in clinical practice.
维普
万方数据